Wegovy contains the same active ingredient, semaglutide, as Ozempic and is manufactured by the same company, Novo Nordisk
doi: 10.1038/s41591-025-04102-x 17
It is not FDA-approved as of April 2026, is not formulated for human consumption or veterinary use, and cannot be legally used to treat, diagnose, or cure any disease
It is ideal to treat the specific areas of stubborn fat that are resistant to diet and exercise
The increased dosage used in Wegovy has been carefully tested and shown to safely promote more substantial reductions in body weight, making it an ideal option for aesthetic patients looking for effective solutions to improve their appearance, confidence, and overall health
In higher doses, it functions as a laxative by drawing water into the intestines, which softens stool and stimulates bowel movements